Clinical Trial Update: BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for BBR 2778 in relapsed, aggressive non-Hodgkin's lymphoma has completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• BBR 2778

Snippet

Sponsor: CTI BioPharma | Conditions: Lymphoma, Non-Hodgkin | Phase 3 | Status: COMPLETED | Results posted: 2017-06-01